Key Findings
The International Diabetes Federation (IDF) Europe has released an expert opinion on the current status and future of Continuous Glucose Monitoring (CGM) as of 2026, concluding that CGM has established itself as an indispensable tool in diabetes management, dramatically improving patients’ quality of life. The new generation of CGM systems further enhances safety, proactive management, and value delivery for a broad spectrum of people with diabetes.
Technical / Clinical Details
IDF Europe’s expert panel highlighted that 2026 CGM systems maintain the essential benefits of earlier approaches, such as 24/7 glucose data provision, while evolving in several aspects. These include smaller and easier-to-apply sensors, improved data transmission reliability, and seamless integration with other digital health tools (e.g., insulin pumps and smartphone apps). Specifically, AI and machine learning algorithms are now integrated with CGM data, enabling more accurate glucose trend predictions, early warnings for hypo- and hyperglycemic events, and personalized insulin dosing recommendations. Clinical evidence demonstrates that widespread CGM use contributes to improved HbA1c values, reduced frequency and severity of hypoglycemic events, and an overall lower risk of diabetes-related complications. The experts strongly advocate an ‘evidence-based, user-centric approach’ when selecting specific CGM systems, considering performance data, clinical evidence, and user needs and preferences.
Background & Context
Diabetes is a growing chronic disease globally, and effective glucose management is crucial for preventing complications and maintaining quality of life. CGM has been a groundbreaking technology in this field, enabling patients to visualize glucose fluctuations and engage in more informed self-management. However, disparities in access to CGM technology, reimbursement systems, and procurement processes exist across regions, posing challenges to equitable utilization. IDF Europe’s recommendations emphasize the importance of collaboration among policymakers, healthcare professionals, patients, and industry stakeholders to address these challenges and maximize the benefits of technological advancements.
Strategic Significance & Outlook
CGM technology is expected to continue evolving beyond 2026, with potential developments including longer-lasting sensors, further miniaturization, and fully implantable devices. IDF Europe argues that future decisions regarding CGM technology selection should consider not just cost but a holistic view encompassing technological performance, clinical effectiveness, and patient needs. This approach will ensure people with diabetes receive high-quality care, and personalized digital health solutions will play a central role in shaping the future of diabetes management.
Source: https://idf.org/europe/news/idf-europe-expert-opinion-continuous-glucose-monitoring-in-2026/
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments